Skip Navigation
Menu
Ideas and Opinions |17 July 2018

A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries

Neeraj Sood, PhD; Diane Ung, JD; Anil Shankar, JD; Brian L. Strom, MD, MPH

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at Annals.org on 15 May 2018.
  • University of Southern California, Los Angeles, California (N.S.)
    Foley & Lardner, Los Angeles, California (D.U., A.S.)
    Rutgers University, Newark, New Jersey (B.L.S.)

    Financial Support: None.

    Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-0186.

    Corresponding Author: Neeraj Sood, PhD, University of Southern California, Verna & Peter Dauterive Hall 210, 635 Downey Way, Los Angeles, CA 90089-3333; e-mail, nsood@healthpolicy.usc.edu.

    Current Author Addresses: Dr. Sood: University of Southern California, Verna & Peter Dauterive Hall 210, 635 Downey Way, Los Angeles, CA 90089-3333.

    Ms. Ung and Mr. Shankar: Foley & Lardner LLP, 555 South Flower Street, Suite 3500, Los Angeles, CA 90071-2411.

    Dr. Strom: Rutgers University, Biomedical and Health Sciences, Stanley S. Bergen Building, 65 Berge Street, Newark, NJ 07103.

    Author Contributions: Conception and design: N. Sood.

    Analysis and interpretation of the data: N. Sood, D. Ung.

    Drafting of the article: N. Sood, D. Ung, A. Shankar.

    Critical revision of the article for important intellectual content: N. Sood, D. Ung, B.L. Strom.

    Final approval of the article: N. Sood, B.L. Strom.

    Administrative, technical, or logistic support: A. Shankar.

×
FULL TEXT
An estimated 2.7 to 3.9 million persons in the United States were living with chronic hepatitis C virus (HCV) infection in 2015 (1). The annual death toll from this condition in the United States exceeds that from HIV and 59 other infectious diseases combined (2). The good news is that curative treatments first introduced in 2013 have achieved a sustained virologic response rate greater than 90% and that sustained virologic response is associated with lower mortality among patients with chronic hepatitis (3, 4). In response, the National Academies of Sciences, Engineering, and Medicine convened a committee of experts to develop a national strategy for eliminating HCV infection as a public health problem. The report concluded that these new treatments could avert nearly 30 000 deaths and reduce incidence of this condition by 90% by 2030 (5).
FULL TEXT
PDF
Not Available
Citations
Citation

Sood N, Ung D, Shankar A, Strom BL. A Novel Strategy for Increasing Access to Treatment for Hepatitis C Virus Infection for Medicaid Beneficiaries. Ann Intern Med. ;169:118–119. doi: 10.7326/M18-0186

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2018;169(2):118-119.

DOI: 10.7326/M18-0186

Published at www.annals.org on 15 May 2018

©
2018 American College of Physicians
1 Citations

Related Articles
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
Annals of Internal Medicine; 163 (3): 215-223
Coverage for Undocumented Migrants Becomes More Urgent
Annals of Internal Medicine; 158 (5_Part_1): 347-348
When Centers for Medicare & Medicaid Services Treats Throat Cancer Like Pharyngitis
Annals of Internal Medicine; 169 (8): 573-574
Persistence and Drivers of High-Cost Status Among Dual-Eligible Medicare and Medicaid Beneficiaries: An Observational Study
Annals of Internal Medicine; 169 (8): 528-534
View MoreView Less

Journal Club
Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1
Annals of Internal Medicine; 161 (10): JC11
View MoreView Less

Related Point of Care
Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
Hepatitis C
Annals of Internal Medicine; 157 (11): ITC6-1
Hepatitis C
Annals of Internal Medicine; 148 (11): ITC6-1
View MoreView Less

Related Topics
Gastroenterology/Hepatology
Healthcare Delivery and Policy
Infectious Disease
Liver Disease
Viral Hepatitis

Gastroenterology/Hepatology, Healthcare Delivery and Policy, Infectious Disease, Liver Disease, Viral Hepatitis.

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×